Non-epithelial ovarian cancer in Denmark – Incidence and survival over nearly 40 years

The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study group

“…There is no evidence for the benefit of hysterectomy or lymphadenectomy [ 6 ]. According to the European Society of Medical Oncology (ESMO), a fertility-retaining approach is indicated for every woman with MOGCT wishing to retain her reproductive potential, even with advanced disease [ 7 , 8 ]. In a retrospective study of a single center in Korea, pregnancy rate reached 75% and live birth rate 65% after fertility-sparing surgery [ 9 ].…”

“…As a third agent, bleomycin or ifosfamid may be added for a total therapeutic length of four cycles [ 6 ]. With this combination of fertility-sparing surgery and combination chemotherapy, 5 year overall survival was high with up to 97% [ 8 , 9 ]. The 5 year disease free survival for all stages was reported with 86% [ 9 ].…”

“…SCSTs are neoplasm of the ovary that represent approximately 1.2 percent of all primary ovarian tumors and are mainly diagnosed in women with a median age around 50 years [ 8 , 10 ]. Surgery is required for staging, and therapy should consist of a median lower laparotomy, inspection and palpation of the abdomen, peritoneal cytology, and tumor removal through salpingo-oophorectomy.…”

“…The benefit of adjuvant chemotherapy also remains uncertain; some patients with FIGO IC disease or with remaining tumor may benefit from platinum-containing protocols [ 6 ]. In a study evaluating incidence and survival for patients with non-epithelial ovarian cancer between 1978 and 2016 in Denmark, the 5 year relative survival of SCST was reported around 74% [ 8 ]. It was lowest in the early study period (51%) and increased during time up to 90%.…”

Imaging in gynecological disease (22): clinical and ultrasound characteristics of ovarian embryonal carcinomas, non‐gestational choriocarcinomas and malignant mixed germ cell tumors

“…Data on the survival of ovarian embryonal carcinomas, non-gestational choriocarcinomas and mixed malignant germ cell tumors are limited owing to the rarity of these tumors. The 5-year overall survival rate for all ovarian non-dysgerminoma germ cell tumors has been reported to be 78% 33,34 , that for ovarian embryonal carcinomas 39-100% 5,32 and that for ovarian mixed malignant germ cell tumors 66.7% 35 . A 3-year overall survival rate of 25-100%, depending on the tumor stage, has been reported for ovarian non-gestational choriocarcinomas 13 .…”